Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial.

McCarty JM, Lock MD, Bennett S, Hunt KM, Simon JK, Gurwith M.

Vaccine. 2019 Mar 7;37(11):1389-1397. doi: 10.1016/j.vaccine.2019.01.077. Epub 2019 Feb 13.

2.

Correction: A clinically parameterized mathematical model of Shigella immunity to inform vaccine design.

Davis CL, Wahid R, Toapanta FR, Simon JK, Sztein MB.

PLoS One. 2018 Apr 19;13(4):e0196367. doi: 10.1371/journal.pone.0196367. eCollection 2018.

3.

Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection.

Haney DJ, Lock MD, Gurwith M, Simon JK, Ishioka G, Cohen MB, Kirkpatrick BD, Lyon CE, Chen WH, Sztein MB, Levine MM, Harris JB.

Vaccine. 2018 May 11;36(20):2768-2773. doi: 10.1016/j.vaccine.2018.04.011. Epub 2018 Apr 11.

4.

Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.

Islam K, Hossain M, Kelly M, Mayo Smith LM, Charles RC, Bhuiyan TR, Kováč P, Xu P, LaRocque RC, Calderwood SB, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB, Qadri F, Ryan ET.

PLoS Negl Trop Dis. 2018 Apr 6;12(4):e0006376. doi: 10.1371/journal.pntd.0006376. eCollection 2018 Apr.

5.

Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.

McCarty JM, Lock MD, Hunt KM, Simon JK, Gurwith M.

Vaccine. 2018 Feb 1;36(6):833-840. doi: 10.1016/j.vaccine.2017.12.062. Epub 2018 Jan 6.

6.

A clinically parameterized mathematical model of Shigella immunity to inform vaccine design.

Davis CL, Wahid R, Toapanta FR, Simon JK, Sztein MB.

PLoS One. 2018 Jan 5;13(1):e0189571. doi: 10.1371/journal.pone.0189571. eCollection 2018. Erratum in: PLoS One. 2018 Apr 19;13(4):e0196367.

7.

Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.

Sow SO, Tapia MD, Chen WH, Haidara FC, Kotloff KL, Pasetti MF, Blackwelder WC, Traoré A, Tamboura B, Doumbia M, Diallo F, Coulibaly F, Onwuchekwa U, Kodio M, Tennant SM, Reymann M, Lam DF, Gurwith M, Lock M, Yonker T, Smith J, Simon JK, Levine MM.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00265-17. doi: 10.1128/CVI.00265-17. Print 2017 Dec.

8.

Accelerating Vaccine Development During the 2013-2016 West African Ebola Virus Disease Outbreak.

Higgs ES, Dubey SA, Coller BAG, Simon JK, Bollinger L, Sorenson RA, Wilson B, Nason MC, Hensley LE.

Curr Top Microbiol Immunol. 2017;411:229-261. doi: 10.1007/82_2017_53. Review.

PMID:
28918539
9.

Identification of immune correlates of protection in Shigella infection by application of machine learning.

Arevalillo JM, Sztein MB, Kotloff KL, Levine MM, Simon JK.

J Biomed Inform. 2017 Oct;74:1-9. doi: 10.1016/j.jbi.2017.08.005. Epub 2017 Aug 9.

10.

Antibody-Based Correlates of Protection Against Cholera Analysis of a Challenge Study in a Cholera-Naïve Population.

Haney DJ, Lock MD, Simon JK, Harris J, Gurwith M.

Clin Vaccine Immunol. 2017 May 31. pii: CVI.00098-17. doi: 10.1128/CVI.00098-17. [Epub ahead of print]

11.

Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.

Halperin SA, Arribas JR, Rupp R, Andrews CP, Chu L, Das R, Simon JK, Onorato MT, Liu K, Martin J, Helmond FA; V920-012 Study Team.

J Infect Dis. 2017 Jun 15;215(12):1789-1798. doi: 10.1093/infdis/jix189.

12.

The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.

Mayo-Smith LM, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Calderwood SB, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00470-16. doi: 10.1128/CVI.00470-16. Print 2017 Jan.

13.

Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.

Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM.

Clin Infect Dis. 2016 Jun 1;62(11):1329-1335. doi: 10.1093/cid/ciw145. Epub 2016 Mar 21.

14.

Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans.

Toapanta FR, Simon JK, Barry EM, Pasetti MF, Levine MM, Kotloff KL, Sztein MB.

Front Immunol. 2014 Aug 20;5:374. doi: 10.3389/fimmu.2014.00374. eCollection 2014.

15.

Applications of nanotechnology for immunology.

Smith DM, Simon JK, Baker JR Jr.

Nat Rev Immunol. 2013 Aug;13(8):592-605. doi: 10.1038/nri3488. Review. Erratum in: Nat Rev Immunol. 2013 Sep;13(9):701.

PMID:
23883969
16.

Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a.

Wahid R, Simon JK, Picking WL, Kotloff KL, Levine MM, Sztein MB.

Clin Immunol. 2013 Jul;148(1):35-43. doi: 10.1016/j.clim.2013.03.009. Epub 2013 Mar 26.

17.

Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics.

Davis CL, Wahid R, Toapanta FR, Simon JK, Sztein MB, Levy D.

PLoS One. 2013 Apr 2;8(4):e59465. doi: 10.1371/journal.pone.0059465. Print 2013.

18.

Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens.

Stanberry LR, Simon JK, Johnson C, Robinson PL, Morry J, Flack MR, Gracon S, Myc A, Hamouda T, Baker JR Jr.

Vaccine. 2012 Jan 5;30(2):307-16. doi: 10.1016/j.vaccine.2011.10.094. Epub 2011 Nov 8.

PMID:
22079079
19.

Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.

Simon JK, Carter M, Pasetti MF, Sztein MB, Kotloff KL, Weniger BG, Campbell JD, Levine MM.

Vaccine. 2011 Nov 28;29(51):9544-50. doi: 10.1016/j.vaccine.2011.09.097. Epub 2011 Oct 8.

PMID:
21986218
20.

Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.

Simon JK, Maciel M Jr, Weld ED, Wahid R, Pasetti MF, Picking WL, Kotloff KL, Levine MM, Sztein MB.

Clin Immunol. 2011 May;139(2):185-92. doi: 10.1016/j.clim.2011.02.003. Epub 2011 Mar 8.

21.

Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine.

Simon JK, Ramirez K, Cuberos L, Campbell JD, Viret JF, Muñoz A, Lagos R, Levine MM, Pasetti MF.

Clin Vaccine Immunol. 2011 Mar;18(3):355-61. doi: 10.1128/CVI.00354-10. Epub 2011 Jan 12.

22.

Immunology of gut mucosal vaccines.

Pasetti MF, Simon JK, Sztein MB, Levine MM.

Immunol Rev. 2011 Jan;239(1):125-48. doi: 10.1111/j.1600-065X.2010.00970.x. Review.

23.

Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.

Wahid R, Pasetti MF, Maciel M Jr, Simon JK, Tacket CO, Levine MM, Sztein MB.

Clin Immunol. 2011 Feb;138(2):187-200. doi: 10.1016/j.clim.2010.11.006. Epub 2010 Dec 10.

24.

Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates.

Simon JK, Wahid R, Maciel M Jr, Picking WL, Kotloff KL, Levine MM, Sztein MB.

Vaccine. 2009 Jan 22;27(4):565-72. doi: 10.1016/j.vaccine.2008.10.081. Epub 2008 Nov 18.

25.

Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media.

Kotloff KL, Simon JK, Pasetti MF, Sztein MB, Wooden SL, Livio S, Nataro JP, Blackwelder WC, Barry EM, Picking W, Levine MM.

Hum Vaccin. 2007 Nov-Dec;3(6):268-75. Epub 2007 Jul 15.

PMID:
17938573
26.

A clinical study to assess the safety and immunogenicity of attenuated measles vaccine administered intranasally to healthy adults.

Simon JK, Pasetti MF, Viret JF, Mischler R, Muñoz A, Lagos R, Levine MM, Campbell JD.

Hum Vaccin. 2007 Mar-Apr;3(2):54-8. Epub 2007 Mar 10.

PMID:
17312403
27.

Intramedullary abscess of the spinal cord in children: a case report and review of the literature.

Simon JK, Lazareff JA, Diament MJ, Kennedy WA.

Pediatr Infect Dis J. 2003 Feb;22(2):186-92. Review.

PMID:
12586985
28.

Improved detection of cytomegalovirus viremia in AIDS patients using shell vial and indirect immunoperoxidase methodologies.

Lipson SM, Kaplan MH, Simon JK, Ciamician Z, Tseng LF.

J Med Virol. 1992 Sep;38(1):36-43.

PMID:
1328510
29.

Effect of renal denervation on plasma renin activity after aortic baroreceptor deafferentation.

Ciriello J, Simon JK, Mercer PF.

Can J Physiol Pharmacol. 1991 Aug;69(8):1237-42.

PMID:
1782607
30.

Cones are not a substitute for specialist physiotherapy.

Simon JK.

Prof Nurse. 1990 Aug;5(11):585. No abstract available.

PMID:
2395891
31.
32.

Afferent renal nerve effects on plasma vasopressin and oxytocin in conscious rats.

Simon JK, Kasting NW, Ciriello J.

Am J Physiol. 1989 Jun;256(6 Pt 2):R1240-4.

PMID:
2735450
33.

Renal denervation alters forebrain hexokinase activity in neurogenic hypertensive rats.

Simon JK, Zhang TX, Ciriello J.

Am J Physiol. 1989 Apr;256(4 Pt 2):R930-8.

PMID:
2705581
34.

Reorganization/diversification: six years later.

Simon JK, Cohen BA.

Health Care Manage Rev. 1989 Fall;14(4):77-84.

PMID:
2599868
35.

Recent trends in childbirth in France.

Simon JK.

Midwife Health Visit Community Nurse. 1984 Jan;20(1):12-3. No abstract available.

PMID:
6570849
36.

The approach to childbirth in France.

Simon JK.

Physiotherapy. 1983 Jul 10;69(7):233-5. No abstract available.

PMID:
6611733
37.

Marketing the community hospital: a tool for the beleaguered administrator.

Simon JK.

Health Care Manage Rev. 1978 Spring;3(2):11-23. No abstract available.

PMID:
10306831
38.

High quality coronary care in the community hospital is necessary and feasible.

Simon JK.

Hosp Manage. 1970 Apr;109(4):33-8. No abstract available.

PMID:
5436426
39.

Hip flexor aid.

SIMON JK.

Phys Ther Rev. 1960 Feb;40:121-2. No abstract available.

PMID:
14446924

Supplemental Content

Loading ...
Support Center